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The potential protective effect of Renin–angiotensin system (RAS) inhibitors is a subject of 
increasing interest due to their possible role as chemopreventive agents against colorectal 
cancer (CRC). To evaluate this association, we conducted a case-control study with 2,165 cases 
of colorectal cancer, diagnosed between 2007 and 2012, and 3,912 population controls 
frequency matched (by age, sex and region) from the Spanish multicenter case-control study 
MCC-Spain.  We found a significant protective effect of the Angiotensin-converting enzyme 
Inhibitors (ACEIs) against CRC, limited to the under-65 years group (OR=0.65 95%CI (0.48-0.89)) 
and to a lesser degree to men (OR=0.81 95%CI (0.66-0.99). In contrast, the angiotensin 
receptor blockers (ARBs) did not show a significant effect.  Regarding the duration of use, a 
greater protection was observed in men as the length of consumption increases. In contrast, in 
the under-65 stratum, the strongest association was found in short-term treatments. Finally, 
by analyzing ACEIs effect by colon subsite, we found no differences, except for under 65 years 
old, where the maximum protection was seen in the proximal intestine, descending in the 
distal and rectum (without statistical significance). In conclusion, our study shows a protective 
effect on CRC of the ACEis limited to males and people under 65 years old, which increases in 
proximal colon in the latter. If confirmed, these results may suggest a novel approach to 
proximal CRC prevention, given the shortcomings of colonoscopy screening in this location. 



















Colorectal cancer (CRC) is one of the most common forms of cancer worldwide with 
approximately 450,000 new cases detected in Europe in 2012 [1, 2]. In the last decades, the 
field of chemoprevention has experimented a rising interest, with the use of certain drugs to 
reduce the individual risk of cancer. Nowadays, the role of aspirin therapy in the reduction of 
colorectal cancer risk and precancerous adenomas [3, 4] is well known and there is increasing 
evidence of the chemopreventive effect of many others drugs used for cardiovascular diseases 
such as statins [5] and renin-angiotensin system (RAS) inhibitors [6].  In addition, recent 
observational studies and one meta-analysis have shown a protective effect of RAS therapy 
against CRC [7- 10].  Despite these encouraging findings, other studies have yielded conflicting 
results [11-13], calling for additional studies before recommending the clinical use of RAS 
inhibitors for CRC chemoprevention. The mechanism of action of the RAS-inhibitors combines 
both pro and antitumor effects, probably explain the controversial results obtained in 
observational studies.  Moreover, the potential interaction with lifestyle factors (eg, diet) 
warrants more investigation [14]. Finally, it is important to identify whether there is a 
differential effect regarding the tumor anatomic subsite, given that, to the best of our 
knowledge, no previous studies have analyzed these aspects.  
 
Therefore, the purpose of this work is to evaluate the effects of Angiotensin-
converting-enzyme inhibitors (ACEis) and Angiotensin receptor blockers (ARBs) on overall 
colorectal cancer risk, and on its different anatomic locations, in a large population-based 
case-control study conducted in Spain, the MCC-Spain study. 
 
MATERIALS AND METHODS 
Study design and population 
We conducted a multi-region case-control study “the Spanish multicase-control study” 
(MCC-Spain). This study was designed with the main objective of investigating lifetime 
environmental, infectious, medical and occupational exposures, as well as genetic factors 
associated with five cancer sites. Briefly, the MCC-Spain is a population-based case-control 
study of common tumors in Spain; the recruitment includes histologically confirmed incident 
cases of colorectal cancer diagnosed between January 1st, 2007 and March 31st, 2012. The 
cases were enrolled in 23 hospitals and primary care centers in 12 Spanish provinces together 
















cancer were randomly selected from lists of primary care centers, according to age, sex and 
regional distribution of the cases included in the study. Response rates were 68% for colon 
cancer cases and 53% for controls, with no differences in the main socio-demographic 
variables among those who participated and those who refused to participate. The Ethics 
Committees of participating hospitals approved the study protocols, and participants provided 
written informed consent at the time of their inclusion in the study.  Detailed clinical 
information was collected for all cases. The questionnaire is available on the website of the 
study (www.mccspain.org). Further information can be found elsewhere [15].  In the present 
study, we have selected only the 2,165 colorectal cancer cases recruited in MCC-Spain and 
their 3,912 frequency matched controls. 
Data collection  
Participants were interviewed face-to-face by trained monitors with a comprehensive 
epidemiological questionnaire that assessed socio-demographic information, personal and 
family history of cancer, anthropometric data, lifestyle, environmental exposure and medical 
history of medication/drugs use. To allow for a minimum latency period, all potential 
confounders that could be modified by the disease (tobacco and alcohol consumption, diet) 
were censored to 1 year prior to the interview. Regarding the life style, diet (including alcohol 
intake) was assessed with the use of a validated semi-quantitative Spanish Food Frequency 
Questionnaire (FFQ), which was modified to include regional products. The FFQ included 140 
food items, and assessed usual dietary intake during the previous year. 
Drug use assessment  
Drugs use was recorded by indication. For each drug, the brand name, dose and 
duration of exposure were recorded to identify patients with regular drug consumption (“no 
and occasionally” versus “yes”) and the duration of consumption (more or less than 5 years).  
The drugs were coded by following the Anatomical Therapeutic Chemical Classification System 
(ATC codes) to define groups with similar mechanisms of action [16].  The ATC code included in 
the present analysis is code C09 (Agents acting on the renin-angiotensin system).  We 
performed the analyses for ACEis drugs and for ARBs. For each of these analyses, we had as 
















proximal colon (including cecum, ascending colon, transverse and hepatic and splenic 
flexures), distal colon (including descending colon, sigmoid and recto-sigmoid junction) and 
rectum. Anatomic subsites were defined according to Li et al [17].  
Statistical Methods 
Unconditional logistic regression was used to assess the association between treatment of 
ACEis and RAS inhibitors and colorectal cancer risk. To estimate the magnitude of the 
associations, multivariate-adjusted odds ratios (OR) and their corresponding 95% confidence 
intervals (CI) were calculated. Multinomial logistic regression was used to assess the 
association between treatment of ACEis and ARBs and colorectal cancer subsites. All models 
included sex, age, province of recruitment (Asturias, Barcelona, Cantabria, Granada, 
Guipuzcoa, Huelva,Leon, Madrid, Murcia, Navarra and Valencia), educational level (less than 
primary school, primary school, secondary school, university), family history of colorectal 
cancer (no, first degree relatives, second degree relatives, others), smoking status one year 
before recruitment  (never; former; current), alcohol consumption in the past (at 30-40 years 
old, in gms/day) and red meat (gms/day) and fruit and vegetable (gms/day) intake one year 
before the diagnosis in cases and the recruitment in controls, as potential confounders. A 
global 5% significance level was used for these analyses and all reported p-values are two-
tailed. The exposure to the RAS inhibitors was analyzed globally and separately by duration of 
treatment (less than or equal to 5 years, or more than 5 years).  Interactions were explored by 
including in the model the multiplicative interaction terms use/no use and sex (male/female), 
age (<65/≥65 years) or BMI (<25 Kg/m2/ ≥25 Kg/m2) respectively. Analyses were performed 
using the package Stata 14/SE (StataCorp, College Station, Tx, US). 
RESULTS 
During the study period, data from 2,165 colorectal cancer cases and 3,912 population 
controls were collected. The characteristics of cases and controls are shown in Table 1.  The 
main differences between cases and controls were found at educational level, family history of 
colon cancer and diet. Controls had higher educational level and less often had a first-degree 
relative with colorectal cancer. Finally, regarding eating habits, controls had lower ethanol, 
energy and red meat intake and higher intake of vegetable. 
 
















The use of ACEis showed a weak protective effect with borderline significance 
(OR=0.89, 95% CI (0.75-1.04)), while no association was observed with the ARB therapy 
(OR=1.00, 95% CI (0.73-1.19). A statistically significant interaction was seen between ACEis 
users and age, where the observed protection was restricted to the under 65 years old group 
(OR under-65=0.65; 95% CI (0.48-0.89) vs OR over-65=1.02 95% CI (0.84-1.24); p for ACEis-age 
interaction=0.03), and between ACEis and sex, where only men were protected (OR men=0.81; 
95% CI (0.66-0.99) vs OR women=1.03 95% CI (0.78-1.37); p for ACEis-sex interaction=0.03). No 
changes were observed when stratifying by BMI (OR=0.85; 95% CI (0.61-1.19) vs OR=0.90 95% 
CI (0.75-1.09); p for ACEis-BMI interaction = 0.68) (Table 2). 
 
Finally, considering the influence of length of consumption (Table 3), an opposite 
(regarding the length of consumption) effect was observed in men and in the under-65 group. 
While in the men group, long-term treatments presented the greatest protection (OR=0.71 
95% CI (0.53-0.95) vs OR=0.91 95%CI (0.71-1.17)), in the under-65 group this effect is 
observed, instead, in short-term treatments (OR= 0.52 95%CI (0.34-0.77)). Stratifying by sex 
and age simultaneously (data not shown), the stronger association was observed in the group 
of men under 65 years old where the ACEis show a protective effect in short (OR= 0.55 95%CI 
(0.35-0.87)) but not long-term treatments (OR= 0.77 95%CI 0.43-1.40)). On the other hand, in 
the group of men over 65 years old, only the length of consumption greater than five years 
showed a protective effect (OR= 0.70 95%CI (0.50-0.99)). 
 
RAS inhibitors and colorectal cancer subsite 
To explore in more detail the potential association between the ACEis and ARBs and 
colon cancer we performed a subanalysis based on the location of neoplastic lesions. 
The protective effect of the ACEIs was observed exclusively in the under 65 years subgroup, 
and was limited to the proximal (OR=0.50 95%CI (0.27-0.92)) and distal colon (OR=0.61 95%CI 
(0.39-0.95) (table 4). This protective benefit of ACEis was less pronounced in men and reached 
only borderline significance (OR=0.73 95%CI (0.51-1.02) in proximal vs OR=0.80 95%CI (0.61-
1.05) in distal colon).  Finally, when stratified by BMI, no significant effect was found.  No 
relationship was observed between treatment with ARBs and colon cancer subsite, neither in 


















In this study, we analyzed a population-based case control study for evaluating the potential 
effect of RAS inhibitors on CRC.  Our study shows a relevant protective effect against CRC for 
the ACEis limited to the under-65 group and to men, but no effect for the ARBs. The stronger 
association was observed in the under 65-year men where the ACEis show a protective effect 
in short term treatments. However, in men over 65, only the length of consumption greater 
than five years showed a protective effect. 
Up to now, existing data regarding the effect of ACEis/ARBs on overall cancer risk are 
contradictory [18-21]. Randomized trials exploring this association usually have follow-up of 
less than five years, insufficient to detect cancer development. Moreover, they focus on 
cardiovascular outcomes as predefined clinical endpoints, being the cancer risk a ‘post-hoc’ 
analysis, thus possibly underreported. For these reasons, we limit our discussion to 
observational studies specifically designed to evaluate cancer. Most of the studies published in 
the last 5 years focusing on CRC have shown that the use of ACEis alone or combined with 
ARBs is associated with a decrease in the risk of CRC development [6, 7, 9], as well as in 
advanced adenomatous colon polyps [8] or advanced neoplasia. In addition, a recently 
published meta-analysis of observational studies [10] also found a protective effect of the 
combination of ACEis or ARBs against CRC.  Regarding overall ACEis effect, we found a similar 
protection to that found in other studies combining ACEis and ARBs in their analyses [9, 10], 
but our results found only borderline significance. It is remarkable that this protection 
increased substantially in the under 65-year age group and less markedly in men. The influence 
of sex on colon cancer incidence is widely known and these differences increase progressively 
across the colon from the cecum to the rectum. Men have higher rates of CRC than women, 
probably due to sex-specific exposure to risk factors, differences in screening experiences and 
access to medical care and protective effects of both endogenous and exogenous hormones 
[22, 23]. In addition, the differential expression of estrogen receptors between the colonic 
subsites might explain the right-sided predominance of the neoplasm in women, even though 
the etiological role of these receptors is not yet well understood [24, 25]. Some studies suggest 
that, over time, the effectiveness of ACE inhibition is diminished in women [26]. These 
differences could be due to a modulatory effect of the sexual steroids on the expression and 
activity of the various components of the RAS, which would explain why the protective effect 
of ACEis was observed only in males in our study [27]. Regarding age differences, a gradual 
















Finally, two recent meta-analyses have shown the influence of obesity and excess weight on 
the risk of developing CRC [31, 32]. Although most of the studies that have conducted analyses 
by CRC subsite have found a significant association between body size and distal adenomas or 
cancer, to date, evidence is still inconsistent [33]. 
Regarding the exposure time, we observed that the protective effect increased in long-
term treatment (>5 years) only in men, while in the under-65 subgroup  the protective effect 
was seen only in treatments lasting less than five years. However, the number of cases and 
controls under-65 exposed to ACEIs for more than five years was rather scarce, which makes it 
difficult to identify a length of treatment – effect relationship. Makar et al [9], also in a case-
control study, found a clear association between long-term or high dose of RAS inhibitors and 
CRC protection.  
On the other hand, the lack of association between ARBs therapy and CRC is consistent with 
others studies [11, 34, 35], which also studied separately the effect of ARBs. In contrast, 
Azoulay et al [7], in a case-control study nested in a cohort, found a weak, but significant 
protection (OR=0.90 95% CI (0.83–0.98)). Focusing on colorectal carcinogenesis, one 
experimental study [36] has demonstrated a beneficial effect of ACEi or ARB therapy reducing 
the total number of colonic premalignant lesions in obese mice. The role of angiotensin II in 
cell proliferation, cell migration, and angiogenesis suggests their participation in certain steps 
of tumor genesis and progression [37], and could explain the antitumor effect of the RAS 
inhibitors (inhibiting tumor angiogenesis, inducing cancer cell apoptosis and disrupting the 
microenvironment of tumor) [38, 39].  However, the mechanisms of action of the two types of 
RAS drugs, ACEis and ARBs, are quite different. While ACEis act inhibiting the conversion of 
angiotensin I to angiotensin II, ARBs act on the receptors of this hormone. The protective 
effect of ACEis has been demonstrated in animal models of solid cancers [40, 41], but certain 
authors have also found that the chronic treatment with ACEis might produce the 
accumulation of some peptides with protumor effect, such as bradykinin, substance P, and N-
acetyl-seryl-aspartyl-lysyl-proline [42]. ARBs, in turn, selectively block the angiotensin II type 1 
receptors, responsible for vasoconstriction, cell growth, and sympathetic activation and in this 
way exerts their potential antineoplastic effect, maintaining the beneficial effects of 
angiotensin II type 2-receptor stimulation (vasodilatory and antiproliferative action mediated 
via the kinin system) [21, 37]. Nevertheless, some studies have suggested a pro-tumoral effect 
of the ARBs as a result of the stimulation of free angiotensin II type 2-receptor, which results in 
















In the last decades, diverse reports have suggested that CRC is a heterogeneous 
disease [45]. At first, distinguishing two distinct categories of CRC, proximal and distal, was 
proposed. Thereafter rectal cancer, which is usually discussed together with colon cancer, was 
addressed specifically as another type of CRC [16]. This is the reason why we have analyzed 
separately the effect of RAS inhibitors according to the colon subsite. Our results show that the 
protective effect observed for ACEis did not reach statistical significance in the analysis by 
location. In the same way, ARBs did not show effect in any of the three locations. However, in 
the under-65 group, ACEis showed a lower protective effect as one progresses through the 
large intestine. Thus, maximum protection was seen in the proximal intestine, descending in 
the distal intestine and rectum, in this last case without statistical significance. In the same 
way, Kedika et al reported a statistically significant decrease in right sided polyps in ACE-I 
users. The fact that young people are less susceptible to developing right-sided colon cancer 
[23] suggests a synergistic interaction between ACEis and age. 
To the best of our knowledge, this is the first study separately addressing the influence 
of the RAS inhibitors on CRC by colon location. It has been speculated that the risk factors for 
CRC may vary according to their anatomic location, because these structures arise from 
different embryonic tissue (the proximal colon from midgut and distal and rectum from 
hindgut) and serve different functions [45, 46]. 
Strengths and limitations 
The strengths of this case-control study include, first, the enrollment of newly 
diagnosed colorectal cancer cases, verified with revision of the medical record and the 
pathological anatomy report, and population controls. Furthermore, all the information has 
been collected by personal interviews identically for cases and controls. This strategy allows us 
to control the principal confounding factors in the relation of RAS inhibitors and colorectal 
cancer (such as family history of colorectal cancer, smoke status, alcohol consumption, age or 
BMI) and include these variables in the adjusted analyses. Notwithstanding these strengths, 
our study has several limitations. First, we used self-reported drug use whereas most studies 
use pharmacy records or prescribing information. Although the validity of self-reported 
medication use has not been assessed in our study, other studies comparing self-reported use 
of antihypertensive medications with pharmacy databases [47] or physician reports [48] have 
showed that self-report is reasonably valid (sensitivity and specificity both being about 90%). 
Second, we were unable to explore a possible association between specific types of drugs 
previously associated with cancer (e.g. Lisinopril, Captopril, Losartan, Candesartan or 
















not explore a dose-response effect of the drugs studied due to the poor quality of these data. 
Therefore, to approach the intensity of the relationship we have chosen to use the duration of 
treatment, considering more exposed those that took the treatment for more than 5 years. 
CONCLUSIONS 
Our study found a protective effect on the CRC risk of the ACEis limited to the under-
65 group and less markedly in men. In those aged under 65 years, this protection shows a 
descending gradient across the colon and disappears in the rectum. Age and sex were 
modifiers of this association. We found no evidence of any effect on colorectal cancer risk 
among those exposed to the ARBs.  
The potential protective effect of RAS inhibitors is a subject of increasing interest due 
to their possible role as chemopreventive agents against CRC [6, 14], but to date, there are still 
few studies that address this relationship. Further work is required to confirm these results, 
but our findings could represent a promising progress in CRC prevention, given the poorer 
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Age, mean±sd 67.0±10.8 63.3±11.8 
Sex, n (%) Men 1383 (63.9) 1995 (51.0) 
Women 782 (36.1) 1917 (49.0) 
Geographical area, n (%) Asturias 77 (3.6) 227 (5.8) 
Barcelona 698 (32.2) 996 (25.5) 
Cantabria 151 (7.0) 355 (9.1) 
Granada 166(7.7) 186 (4.8) 
Guipuzcoa 119 (5.5) 352 (9.0) 
Huelva 74 (3.4) 174 (4.5) 
Leon 405 (11.3) 440 (11.3) 
Madrid 233 (10.8) 726 (18.6) 
Murcia 36 (1.7) 42 (1.1) 
Navarra 125 (5.8) 266 (6.8) 
Valencia 81 (3.8) 148 (3.8) 
Family history of colon cancer, n 
(%) 
No 1679 (79.4) 3487 (88.8) 
First-degree 
relative 




78 (3.7) 110 (2.8) 
Educational level, n (%) Less than 
primary school 
695 (32.1) 740 (18.9) 
Primary 
school 
826 (38.2) 1273 (32.6) 
Secondary 
school 
430 (19.9) 1109 (28.4) 
University 214 (9.9) 790 (20.2) 
Tobacco smoking, n (%) Never smoker 893 (41.3) 1739 (44.5) 
Former 
smoker 
999 (46.1) 1420 (36.3) 
Current 
smoker 
273 (12.6) 753 (19.3) 
Body Mass Index (kg/m
2
), n (%) <18.5 20 (0.9) 48 (1.2) 
18.5-24.9 650 (30.0) 1420 (36.3) 
25.0-29.9 960 (44.3) 1620 (41.4) 
≥30 535 (24.7) 824 (21.1) 
Energy intake (kcal/day), mean±sd 2008.4±708.2 1893±637.6 
Ethanol intake (g/day), mean±sd 23.9±34.6 17.1±26.8 
Red meat intake (g/day), mean±sd 34.7±28.6 29.5±23.4 
Fruit intake (g/day), mean±sd 343.5±205.3 347.5±218.5 
Vegetable intake (g/day), mean±sd 174.8±113.2 189±123.4 
1















Table 2. Relationship between Renin–angiotensin system inhibitors and colorectal cancer 









 and controls 3389/1842 523/323 0.89 (0.75-1.04) 
Men 1649/1171 346/212 0.81 (0.66-0.99) 
Women 1740/671 177/111 1.03 (0.78-1.37) 
<65 years, 1735/770 173/76 0.65 (0.48-0.89) 
≥65 years 1654/1072 350/247 1.02 (0.84-1.24) 
BMI<25Kg/m
2
 1329/597 139/73 0.85 (0.61-1.19) 
BMI≥25Kg/m
2
 2060/1245 384/250 0.90 (0.75-1.09) 
Angiotensin receptor blockers All cases
1
 and controls 3523/1904 389/261 1.00 (0.73-1.19) 
 Men 1744/1222 251/161 0.88 (0.70-1.10) 
 Women 1779/682 138/100 1.29 (0.96-1.75) 
 <65 years 1804/785 104/61 0.89 (0.62-1.27) 
 ≥65 years 1719/1119 285/200 1.04 (0.84-1.29) 
 BMI<25Kg/m
2
 1400/620  68/50 1.30 (0.86-1.95) 
 BMI≥25Kg/m
2
 2123/1284 321/211 0.94 (0.77-1.16) 
OR: Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of  colorectal  cancer, Ethanol intake (g/day) 
Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 
1















Table 3. Relationship between Renin–angiotensin system inhibitors consumption and colorectal cancer, according to length of consumption 
 
Antihypertensive drug Population No consumption Consumption≤5y  Consumption>5y  
  Controls/cases 
(n) 
Controls/cases (n) OR (95% CI) Controls/cases 
(n) 







3389/1842 275/171 0.90 (0.72-1.11) 248/152 0.88 (0.70-1.11) 
Men 1649/1171 184/127 0.91 (0.71-1.17) 162/85 0.71 (0.53-0.95) 
Women 1740/671   91/44 0.89 (0.59-1.34) 86/67 1.18 (0.82-1.69) 
<65 years 1735/770 111/41 0.52 (0.34-0.77) 62/35 0.91 (0.57-1.45) 
≥65 years 1654/1072 164/130 1.16 (0.89-1.51) 186/117 0.91 (0.70-1.18) 
BMI<25Kg/m
2
 1329/597  76/48 0.99 (0.65-1.50)  63/25 0.69(0.41- 1.14) 
BMI≥25Kg/m
2
 2060/1245 199/123 0.86 (0.67-1.11) 185/127 0.95 (0.74 1.23) 




3523/1904 222/153 1.02 (0.82-1.29) 167/108 0.88 (0.70-1.11) 
 Men 1744/1222 144/99 0.95 (0.72-1.27) 107/62 0.77 (0.54-1.08) 
 Women 1779/682  78/54 1.18 (0.80-1.74) 60/46 1.45 (0.94-2.25) 
 <65 years 1804/785  59/40 0.92 (0.59-1.44) 45/21 0.82 (0.46-1.44) 
 ≥65 years 1719/1119 163/113 1.05 (0.80-1.38) 122/87 1.02 (0.74-1.39) 
 BMI<25Kg/m
2
 1400/620  42/33 1.35 (0.82-2.22) 26/17 1.21 (0.62-2.3) 
 BMI≥25Kg/m
2
 2123/1284 180/120 0.96 (0.74-1.24) 141/91 0.92 (0.68-1.23) 
OR: Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of  colorectal  cancer,. Ethanol intake (g/day) 
Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 
1





















Table 4. Relationship between Angiotensin-converting-enzyme inhibitors and colon cancer by location  




OR (95% CI) 
All cases
1
 and controls Proximal colon 3385/488 523/85 0.87 (0.67-1.13) 
Distal  colon 3385/749 523/126 0.83 (0.66-1.03) 
Rectal cancer 3385/562 523/106 1.00 (0.79-1.27) 
Men  Proximal colon  1649/288 346/46 0.73 (0.51-1.02) 
Distal colon 1649/469 346/88 0.80 (0.61-1.05) 
Rectal cancer 1649/382 346/74 0.92 (0.69-1.17) 
Women Proximal colon  1740/200 177/39 1.15 (0.76-1.72) 
Distal colon 1740/280 177/38 0.87 (0.58-1.29) 
Rectal cancer 1740/180 177/32 1.18(0.76-1.83) 
<65 years Proximal colon  1735/182 173/13 0.50 (0.27-0.92) 
Distal colon 1735/302 173/29 0.61(0.39-0.95) 
Rectal cancer 1735/274 173/32 0.77 (0.50-1.20) 
≥65 years Proximal colon  1654/306 350/72 1.04(0.77-1.39) 
Distal colon 1654/447 350/97 0.96(0.74-1.25) 





Proximal colon  1329/151 139/17 0.81 (0.46-1.42)   
Distal colon 1329/232 139/24 0.67 (0.41- 1.09)    
Rectal cancer 1329/203 139/30 1.10 (0.70-1.75) 
BMI≥25Kg/m
2
 Proximal colon  2060/337 384/68 0.89 (0.67-1.20) 
Distal colon 2060/517 384/102 0.88 (0.68-1.13) 
Rectal cancer 2060/359 384/76 0.95 (0.72-1.27) 
OR: Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of  colorectal  cancer, Ethanol intake (g/day) 
Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 
1














Table 5. Relationship between Angiotensin receptor blockers and colon cancer by location  
 
OR: Odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI, family history of  colorectal  cancer,. Ethanol intake (g/day) 
Red meat intake (g/day), Fruit intake (g/day), Vegetable intake (g/day), CI: confidence interval 
1
All cases were diagnosed between 2007 and 2012. 




OR (95% CI) 
All cases
1
 and controls Proximal colon 3523/491 389/82 1.17 (0.89-1.53) 
Distal  colon 3523/765 389/110 1.02 (0.81-1.30) 
Rectal cancer 3523/603 389/65 0.86(0.64-1.15) 
Men  Proximal colon  1744/288 251/46 1.04 (0.73-1.49) 
Distal colon 1744/487 251/70 0.91 (0.67-1.23) 
Rectal cancer 1744/414 251/42 0.76 (0.53-1.09) 
Women Proximal colon  1779/203 138/36 1.39 (0.91-2.12) 
Distal colon 1779/278 138/40 1.31 (0.88-1.96) 
Rectal cancer 1779/189 138/23 1.17(0.71-1.93) 
<65 years Proximal colon  1804/180 104/15 0.91 (0.50-1.66) 
Distal colon 1804/301 104/30 1.18(0.75-1.85) 
Rectal cancer 1804/290 104/16 0.64 (0.36-1.13) 
≥65 years Proximal colon  1719/311 285/67 1.27 (0.93-1.73) 
Distal colon 1719/464 285/80 0.98(0.74-1.30) 
Rectal cancer 1719/313 285/49 0.96 (0.68-1.35) 
BMI < 25Kg/m
2
 Proximal colon  1400/157 68/11 0.96 (0.48-1.91)    
Distal colon 1400/232 68/24 1.64 (0.98- 2.75)   
Rectal cancer 1400/218 68/15 1.26 (0.68-2.34) 
BMI≥25Kg/m
2
 Proximal colon  2123/334 321/71 1.21 (0.90-1.62) 
Distal colon 2123/533 321/86 0.92 (0.70-1.20) 





















 Angiotensin-converting enzyme inhibitors protect against colorectal cancer. 
 This effect is limited to males and people under 65 years old. 
 The stronger association is observed in proximal colon.  
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